Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET
Company Participants
Elhan Webb – Senior Vice President, Investor Relations
Richard Paulson – President and Chief Executive Officer
Reshma Rangwala – Chief Medical Officer
Sohanya Cheng – Chief Commercial Officer
Michael Mason – Chief Financial Officer
Conference Call Participants
Brian Abrahams – RBC Capital Markets
Ed White – H.C. Wainwright
Peter Lawson – Barclays
Maury Raycroft – Jefferies
Operator
Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to Karyopharm Therapeutics Third Quarter 2024 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request.
I would now like to turn the call over to Elhan Webb, Senior Vice President, Investor Relations.
Elhan Webb
Thank you. And thank you all for joining us on today’s conference call to discuss Karyopharm’s third quarter Q2 2024 financial results and recent company progress. We issued a press release this morning detailing our financial results for third quarter 2024. This release, along with a slide presentation that I will reference during our call today are available on our website.
For today’s call, as seen on slide two, I’m joined by Richard, Reshma, Sohanya and Mike who will provide an update on our results for the third quarter 2024 and recent clinical developments.
Before we begin our formal comments, I’ll remind you that various remarks will make today constitute forward-looking statements, FLS for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide three. Actual results may differ materially from those indicated by this FLS as a result of various important factors, including those discussed in the Risk
Credit: Source link
